Crescenza Pasciolla
A5080840329- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Neutropenia and Cancer Infections
- Pneumocystis jirovecii pneumonia detection and treatment
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- Epigenetics and DNA Methylation
- Tuberculosis Research and Epidemiology
- Long-Term Effects of COVID-19
- Cytomegalovirus and herpesvirus research
- Hematological disorders and diagnostics
- Antifungal resistance and susceptibility
- Hematopoietic Stem Cell Transplantation
- SARS-CoV-2 and COVID-19 Research
- Cancer Treatment and Pharmacology
- Neonatal Health and Biochemistry
- Retinal and Optic Conditions
- Reproductive Biology and Fertility
- Sarcoma Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Blood disorders and treatments
- Adolescent and Pediatric Healthcare
Istituto Tumori Bari
2019-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2025
University of Bari Aldo Moro
2013-2017
Ospedale Pediatrico Giovanni XXIII
2016-2017
The potential for visually detectable clinical signs of anaemia and their correlation with the severity pathology have supported research on non-invasive prevention methods. Physical examination a suspected diagnosis is practice performed by specialist to evaluate pallor exposed tissues. aim presented herein quantify minimize subjective nature palpebral conjunctiva, suggesting method diagnostic support autonomous monitoring. Here we describe methodology system extracting key data from...
Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and allogeneic stem cell transplantation (HSCT). We evaluated toxicity efficacy of CPX-351 in 71 elderly patients (median age 66 years) with sAML enrolled the Italian Named (Compassionate) Use Program. Sixty days treatment-related mortality was 7% (5/71). The response rate at end treatment was: CR/CRi 50/71 (70.4%), PR 6/71 (8.5%), NR 10/71 (19.7%). After a median follow-up 11 months relapse observed 10/50...
Unlike other cases of acute leukemia, the diagnosis T-cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) is uniquely based on morphology and flow cytometry. Although genomic background has been broadly uncovered, large spectrum genes involved variability molecular mechanisms underlying gene deregulation have delayed introduction cytogenetics into diagnostic flowcharts. To overcome these limitations implement a genetic T-ALL/LBLs, we repurpose whole transcriptome expression assay (WTEa) as...
<title>Abstract</title> A real-life study on CPX-351 and the standard arm (‘7 + 3’) of registrative trial in adults with secondary Acute Myeloid Leukemia were compared by an unanchored Matching-adjusted indirect comparison (MAIC), order to evaluate efficacy toxicity CPX-351. Results this are important confirm role significantly improving survival remission rates ‘7 3’ a good safety profile AML patients high-risk features, target group traditionally very poor prognosis. Moreover, pilot...
Introduction: Remdesivir (REM) and monoclonal antibodies (mAbs) could alleviate severe COVID-19 in at-risk outpatients. However, data on their use hospitalized patients, particularly elderly or immunocompromised hosts, are lacking. Methods: All consecutive patients with at our unit from 1 July 2021 to 15 March 2022 were retrospectively enrolled. The primary outcome was the progression (P/F < 200). Descriptive statistics, a Cox univariate–multivariate model, an inverse probability...
High rates of lung failure have been reported in haematological patients after SARS-CoV2 infection. An early administration monoclonal antibodies or anti-virals may improve the prognosis. Oral a wider use independently genetic variations virus. Prospective data on malignancies (HMs) are still lacking. Outpatients diagnosed with HM and COVID-19 infection were prospectively treated oral nirmatrelvir/ritonavir molnupiravir. Incidence failure, deaths adverse events was analysed. Long-term...
The potential drug-drug interactions of midostaurin may impact the choice antifungal (AF) prophylaxis in FLT3-positive acute myeloid leukemia (AML) patients. To evaluate incidence invasive fungal diseases (IFD) during treatment FLT3-mutated AML patients and to correlate it different AF strategies, we planned a multicenter observational study involving 15 SEIFEM centers. One hundred fourteen treated with chemotherapy + as induction/reinduction, consolidation or both were enrolled. During...
Midostaurin is used in combination with chemotherapy to treat patients newly diagnosed FLT3-mutated acute myeloid leukemia. Chemotherapy-induced neutropenia exposes these a significant risk of invasive fungal infections (IFIs). International guidelines recommend primary antifungal prophylaxis posaconazole (PCZ) but nested analysis phase III trial showed that strong PCZ inhibition CYP3A4 diminished midostaurin metabolism and increased plasma levels; however, midostaurin-related adverse events...
The introduction of pediatric-inspired regimens in adult Philadelphia-negative acute lymphoblastic leukemia (Ph-ALL) has significantly improved patients' prognosis. Within the Campus ALL network we analyzed outcome Ph-ALL patients treated according to GIMEMA LAL1913 protocol outside clinical trial, compare real-life data with study results. We included 421 consecutive patients, a median age 42 years. complete remission (CR) rate after first course chemotherapy was 94% and measurable residual...
Not available.
Blinatumomab is the first bi-specific T-cell engager approved for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (B-ALL). Despite remarkable clinical results, effects of blinatumomab on host immune cell repertoire are not fully elucidated. In present study, we characterized peripheral blood (PB) and, time, bone marrow (BM) upon treatment. Twenty-nine patients with B-ALL received according to practice. Deep multiparametric flow cytometry was used characterize lymphoid...
Decitabine, a DNA hypomethylating agent, was approved for use in adults with acute myeloid leukemia (AML) not eligible standard chemotherapy and is now widely accepted as treatment. Although number of clinical trials demonstrated its benefits elderly AML patients, older patients frequent comorbidities are typically under-represented such settings. Thus, the aim present study to evaluate, real-world setting, effectiveness toxicity decitabine administered single agent unselected previously...
Summary Within the Campus ALL network we analyzed incidence, characteristics, treatment and outcome of a central nervous system (CNS) relapse in 1035 consecutive adult acute lymphoblastic leukemia (ALL) patients treated frontline with pediatric‐inspired protocols between 2009 2020. Seventy‐one (6.8%) experienced CNS recurrence, more frequently T‐ (28/278; 10%) than B‐ALL (43/757; 5.7%) ( p = 0.017). An early relapse—< 12 months from diagnosis—was observed 41 patients. In multivariate...
Abstract Backgroud: The prognosis of B cell ALL patients (pts) relapsing after Hematopoietic Transplant is poor and new drugs are needed. In acute myeloid leukemia, FLT3-inhibitors (FLT3i) showing promising results in FLT3-mutated (mut) cases. Their potential use FLT3-mut B-ALL has been poorly investigated. Aim: To assess if FLT3 could be a valid targetable marker B-ALL. Methods: We sequenced with capture based large RNA-seq panel (1385genes) 183 adult [n=52 Pos for Ph or t(4;11) t(1;19)...
In the present study, we aimed to evaluate absolute risk of infection in real-life setting AML patients treated with CPX-351. The study included all from 30 Italian hematology centers SEIFEM group who received CPX-351 July 2018 June 2021. There were 200 included. Overall, 336 courses counted: first induction cycle, 18 (5%) a second induction, while 86 (26%) proceeded consolidation and 32 (10%) consolidation. A total 249 febrile events recorded: 193 during or 56 after After diagnostic...